AUS
NZ
UK
CA
USA
IND
Highlights
- PME delivers radiology tech that supports faster diagnostics
- Healthcare sector offers stable revenue and long-term growth
- PME trades at a premium valuation with rising revenue
Pro Medicus (ASX:PME), a leading healthcare technology provider, has seen its share price fall by 17% since the start of 2025. Despite the dip, the company remains a standout in a sector that’s becoming increasingly attractive to investors focused on long-term trends and innovation.
Founded in 1983, Pro Medicus delivers radiology IT software used across hospitals, imaging centres, and healthcare networks around the world. Its core products span Radiology Information Systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualisation tools. These solutions streamline patient scheduling, billing, image interpretation, and clinical analysis.
A key differentiator is its Visage software, designed to help radiologists view large X-ray images remotely on mobile devices. This functionality empowers clinicians to make faster decisions, potentially improving patient outcomes through better accessibility and real-time diagnostics.
From a broader perspective, the healthcare sector is earning fresh attention, especially as it offers more stable and consistent revenue compared to more cyclical industries. The S&P/ASX 200 Healthcare Index (ASX:XHJ) has underperformed the broader ASX 200 over the past five years, but many still consider healthcare companies resilient due to their role in essential services.
Several trends are adding to the sector’s appeal. Healthcare expenditure remains one of the last areas to see cutbacks during economic uncertainty, giving companies like Pro Medicus steady income flows. Historically, the sector has performed strongly during downturns, including the global financial crisis.
Growth potential is also strong. With the US accounting for over 40% of global healthcare spending—and that spending expected to grow by 7% annually through to 2027—companies providing software, digital services, and analytics stand to benefit. Healthcare IT and SaaS-focused firms are forecast to expand revenue by more than 15% annually between 2024 and 2030.
Moreover, interest in ethical and sustainable investing continues to grow. Healthcare, seen as a sector providing social value, is attracting capital from investors aligning their portfolios with positive impact.
Looking at valuation, Pro Medicus currently trades at a price-to-sales ratio of 135.52x, well above its 5-year average of 82.69x. While this may signal a premium, the company has continued to grow its revenue over recent years, offering context behind its higher multiple.
Its innovative product offerings and alignment with macro healthcare trends, Pro Medicus (PME) remains a name to keep an eye on in the healthcare tech space.
